The reiteration of the 'Sector Perform' rating and maintained price target by RBC Capital indicates that the analyst sees the stock performing in line with the sector average. This is neither a strong buy nor sell signal, hence the neutral score. However, the news is highly relevant as it directly pertains to Enanta Pharma and is important for investors tracking analyst ratings and price targets.